Literature DB >> 20516069

The cdk5 kinase regulates the STAT3 transcription factor to prevent DNA damage upon topoisomerase I inhibition.

Sandy Courapied1, Hélène Sellier, Sophie de Carné Trécesson, Arnaud Vigneron, Anne-Charlotte Bernard, Erick Gamelin, Benjamin Barré, Olivier Coqueret.   

Abstract

The STAT3 transcription factors are cytoplasmic proteins that induce gene activation in response to growth factor stimulation. Following tyrosine phosphorylation, STAT3 proteins dimerize, translocate to the nucleus, and activate specific target genes involved in cell-cycle progression. Despite its importance in cancer cells, the molecular mechanisms by which this protein is regulated in response to DNA damage remain to be characterized. In this study, we show that STAT3 is activated in response to topoisomerase I inhibition. Following treatment, STAT3 is phosphorylated on its C-terminal serine 727 residue but not on its tyrosine 705 site. We also show that topoisomerase I inhibition induced the up-regulation of the cdk5 kinase, a protein initially described in neuronal stress responses. In co-immunoprecipitations, cdk5 was found to associate with STAT3, and pulldown experiments indicated that it associates with the C-terminal activation domain of STAT3 upon DNA damage. Importantly, the cdk5-STAT3 pathway reduced DNA damage in response to topoisomerase I inhibition through the up-regulation of Eme1, an endonuclease involved in DNA repair. ChIP experiments indicated that STAT3 can be found associated with the Eme1 promoter when phosphorylated only on its serine 727 residue and not on tyrosine 705. We therefore propose that the cdk5-STAT3 oncogenic pathway plays an important role in the expression of DNA repair genes and that these proteins could be used as predictive markers of tumors that will fail to respond to chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20516069      PMCID: PMC2930675          DOI: 10.1074/jbc.M109.092304

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  58 in total

Review 1.  What does Stat3 do?

Authors:  David E Levy; Chien-kuo Lee
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

Review 2.  Stat proteins and oncogenesis.

Authors:  Jacqueline Bromberg
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

3.  Transcriptional regulation by a DNA-associated form of cyclin D1.

Authors:  Frédéric Bienvenu; Benjamin Barré; Sandrine Giraud; Sylvie Avril; Olivier Coqueret
Journal:  Mol Biol Cell       Date:  2005-01-19       Impact factor: 4.138

4.  BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance.

Authors:  A Slupianek; C Schmutte; G Tombline; M Nieborowska-Skorska; G Hoser; M O Nowicki; A J Pierce; R Fishel; T Skorski
Journal:  Mol Cell       Date:  2001-10       Impact factor: 17.970

Review 5.  A decade of CDK5.

Authors:  R Dhavan; L H Tsai
Journal:  Nat Rev Mol Cell Biol       Date:  2001-10       Impact factor: 94.444

6.  Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation.

Authors:  Jinbo Yang; Moitreyee Chatterjee-Kishore; Susan M Staugaitis; Hannah Nguyen; Karni Schlessinger; David E Levy; George R Stark
Journal:  Cancer Res       Date:  2005-02-01       Impact factor: 12.701

7.  Functional interaction of STAT3 transcription factor with the coactivator NcoA/SRC1a.

Authors:  Sandrine Giraud; Frédéric Bienvenu; Sylvie Avril; Hugues Gascan; David M Heery; Olivier Coqueret
Journal:  J Biol Chem       Date:  2001-12-31       Impact factor: 5.157

8.  Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis.

Authors:  Artur Slupianek; Grazyna Hoser; Ireneusz Majsterek; Agnieszka Bronisz; Maciej Malecki; Janusz Blasiak; Richard Fishel; Tomasz Skorski
Journal:  Mol Cell Biol       Date:  2002-06       Impact factor: 4.272

Review 9.  Apoptosis: a link between cancer genetics and chemotherapy.

Authors:  Ricky W Johnstone; Astrid A Ruefli; Scott W Lowe
Journal:  Cell       Date:  2002-01-25       Impact factor: 41.582

10.  STAT1: a modulator of chemotherapy-induced apoptosis.

Authors:  Michelle Thomas; Clodagh E Finnegan; Katherine M-A Rogers; James W Purcell; Anne Trimble; Patrick G Johnston; Marion P Boland
Journal:  Cancer Res       Date:  2004-11-15       Impact factor: 12.701

View more
  39 in total

Review 1.  Cdk5: mediator of neuronal development, death and the response to DNA damage.

Authors:  Jinqiu Zhu; Wenming Li; Zixu Mao
Journal:  Mech Ageing Dev       Date:  2011-05-11       Impact factor: 5.432

2.  A quantitative proteomic approach of the different stages of colorectal cancer establishes OLFM4 as a new nonmetastatic tumor marker.

Authors:  Damien Besson; Aude-Hélène Pavageau; Isabelle Valo; Anthony Bourreau; Audrey Bélanger; Caroline Eymerit-Morin; Alice Moulière; Agnès Chassevent; Michelle Boisdron-Celle; Alain Morel; Jerôme Solassol; Mario Campone; Erick Gamelin; Benjamin Barré; Olivier Coqueret; Catherine Guette
Journal:  Mol Cell Proteomics       Date:  2011-10-10       Impact factor: 5.911

3.  Phosphoregulation of the RNA-binding protein Hu antigen R (HuR) by Cdk5 affects centrosome function.

Authors:  Natalia Filippova; Xiuhua Yang; Peter King; L Burt Nabors
Journal:  J Biol Chem       Date:  2012-07-24       Impact factor: 5.157

4.  SH2B1β interacts with STAT3 and enhances fibroblast growth factor 1-induced gene expression during neuronal differentiation.

Authors:  Yu-Jung Chang; Kuan-Wei Chen; Ching-Jen Chen; Ming-Hsing Lin; Yuh-Ju Sun; Jia-Lin Lee; Ing-Ming Chiu; Linyi Chen
Journal:  Mol Cell Biol       Date:  2014-01-06       Impact factor: 4.272

Review 5.  Chemotherapy-induced senescence, an adaptive mechanism driving resistance and tumor heterogeneity.

Authors:  Jordan Guillon; Coralie Petit; Bertrand Toutain; Catherine Guette; Eric Lelièvre; Olivier Coqueret
Journal:  Cell Cycle       Date:  2019-08-09       Impact factor: 4.534

6.  Escape from p21-mediated oncogene-induced senescence leads to cell dedifferentiation and dependence on anti-apoptotic Bcl-xL and MCL1 proteins.

Authors:  Sophie de Carné Trécesson; Yannis Guillemin; Audrey Bélanger; Anne-Charlotte Bernard; Laurence Preisser; Elisa Ravon; Erick Gamelin; Philippe Juin; Benjamin Barré; Olivier Coqueret
Journal:  J Biol Chem       Date:  2011-02-03       Impact factor: 5.157

7.  Aberrantly activated pSTAT3-Ser727 in human endometrial cancer is suppressed by HO-3867, a novel STAT3 inhibitor.

Authors:  Brent J Tierney; Georgia A McCann; Shan Naidu; Kellie S Rath; Uksha Saini; Ross Wanner; Periannan Kuppusamy; Adrian Suarez; Paul J Goodfellow; David E Cohn; Karuppaiyah Selvendiran
Journal:  Gynecol Oncol       Date:  2014-07-16       Impact factor: 5.482

Review 8.  Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution.

Authors:  Uddalak Bharadwaj; Moses M Kasembeli; Prema Robinson; David J Tweardy
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

9.  Critical role for lysine 685 in gene expression mediated by transcription factor unphosphorylated STAT3.

Authors:  Maupali Dasgupta; Hamiyet Unal; Belinda Willard; Jinbo Yang; Sadashiva S Karnik; George R Stark
Journal:  J Biol Chem       Date:  2014-09-12       Impact factor: 5.157

10.  Inhibition of STAT3 enhances the radiosensitizing effect of temozolomide in glioblastoma cells in vitro and in vivo.

Authors:  Tae Jin Han; Bong Jun Cho; Eun Jung Choi; Dan Hyo Kim; Sang Hyuk Song; Sun Ha Paek; In Ah Kim
Journal:  J Neurooncol       Date:  2016-08-10       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.